Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

BIOLOGICAL

SL-T10

A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants

BIOLOGICAL

GX-I7

A T-cell growth factor

BIOLOGICAL

Pembrolizumab

An immune check point inhibitor

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

SL VAXiGEN

INDUSTRY